Instrument Inactif

Communiqués ValiRx Plc London S.E.

Actions

Cours en clôture London S.E. Autres places de cotation
- ^GBX	-

23/06	RÉSULTATS ET ACTIVITÉ : Le bénéfice de ValiRx recule ; Ukrproduct réduit sa perte	AN
22/06	Maintel boucle sa levée de fonds ; ValiRx met fin à un accord	AN

24/03/25	ValiRx PLC - Director Disclosure Update	AQ
19/09/24	ValiRx plc - Inaphaea Evaluation and Commercial Use Agreement	AQ
06/12/23	ValiRx strikes deal with Ambrose Healthcare to license late-stage cancer treatment	AQ
01/02/23	ValiRx signals launch of new strategy with Nottingham laboratories	AQ
16/12/22	ValiRx appoints preclinical project manager to drive development of triple breast cancer treatment	AQ
25/10/22	ValiRx signs IP license agreement with Kings College London to progress triple negative breast cancer treatment	AQ
20/10/22	ValiRx appoints NED to support growth and investment drive	AQ
12/10/22	ValiRx Plc - Ada Lovelace Day 2022, in conversation with ValiRx's CEO	AQ
30/09/20	ValiRx : Exercise of Warrant	AQ
24/09/20	ValiRx : Share Price Movement, Exercise of Warrant	AQ
15/09/20	ValiRx : Exercise of Warrants and Warrant Update	AQ
08/09/20	VALIRX : HALF YEARLY REPORT FOR THE PERIOD ENDED 30 JUNE 2020	AQ
08/09/20	ValiRx : Exercise of Warrant	AQ
31/08/20	ValiRx : Exercise of Warrants	AQ
20/08/20	ValiRx : Block Listing Application and Company Update	AQ
10/08/20	ValiRx : Director Dealing	AQ
27/07/20	ValiRx : Broker Option, Fully Subscribed	AQ
24/07/20	ValiRx : Result of AGM	AQ
24/07/20	ValiRx : Oversubscribed Placing and Fundraise	AQ
24/07/20	ValiRx : Pre-AGM Statement	AQ
02/07/20	ValiRx : Notice of AGM	AQ
04/05/20	ValiRx : Share Price Movement	AQ
04/05/20	ValiRx : Proposed appointment of Director	AQ
15/04/20	ValiRx : Result of General Meeting and Directorate Change	AQ
15/04/20	ValiRx : Change of Director	AQ